Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
156.86
+3.05 (1.98%)
At close: Oct 27, 2026, 4:00 PM EDT
156.49
-0.37 (-0.24%)
After-hours: Oct 27, 2026, 7:49 PM EDT
Novartis AG Revenue
Novartis AG had revenue of $15.03B in the quarter ending September 30, 2026, with 4.67% growth. This brings the company's total for the last twelve months to $57.36B, up 1.76% year-over-year. In the year 2025, Novartis AG had annual revenue of $56.67B with 9.57% growth.
Revenue (ttm)
$57.36B
Revenue Growth
+1.76%
P/S Ratio
5.15
Revenue / Employee
$762,140
Employees
75,267
Market Cap
301.22B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Novartis AG breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.67B | 4.95B | 9.57% |
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | -5.17B | -9.97% |
| Dec 31, 2022 | 51.83B | -1.05B | -1.98% |
| Dec 31, 2021 | 52.88B | 2.98B | 5.97% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | 46.10B | -4.04B | -8.05% |
| Dec 31, 2017 | 50.14B | 699.00M | 1.41% |
| Dec 31, 2016 | 49.44B | -951.00M | -1.89% |
| Dec 31, 2015 | 50.39B | -3.25B | -6.05% |
| Dec 31, 2014 | 53.63B | 918.00M | 1.74% |
| Dec 31, 2013 | 52.72B | 745.00M | 1.43% |
| Dec 31, 2012 | 51.97B | -7.40B | -12.47% |
| Dec 31, 2011 | 59.38B | 7.81B | 15.15% |
| Dec 31, 2010 | 51.56B | 6.46B | 14.32% |
| Dec 31, 2009 | 45.10B | 2.52B | 5.92% |
| Dec 31, 2008 | 42.58B | 3.64B | 9.34% |
| Dec 31, 2007 | 38.95B | 3.84B | 10.94% |
| Dec 31, 2006 | 35.11B | 5.35B | 17.99% |
| Dec 31, 2005 | 29.75B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 99.34B |
| Merck & Co. | 66.57B |
| AbbVie | 64.39B |
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
| Bristol-Myers Squibb Company | 49.19B |
NVS News
- 2 hours ago - What Novartis (NVS) Said on Its Q3 Earnings Call - MarketBeat
- 8 hours ago - Novartis (NVS) Raises 2026 Profit Outlook Amid AI Cost Savings - GuruFocus
- 9 hours ago - Novartis Stocks Gain With Higher Guidance but Weaker Cash Generation - GuruFocus
- 12 hours ago - Novartis Hikes Income Forecast, But There Were Caveats Within Its Report - Investor's Business Daily
- 12 hours ago - Novartis (NVS) Raises 2025 Profit Outlook Amid Strong Demand for New Drugs - GuruFocus
- 13 hours ago - Novartis AG Earnings Call Transcript: Q3 2026 - Transcripts
- 13 hours ago - Novartis AG Earnings release: Q3 2026 - Filings
- 13 hours ago - Novartis AG Slides: Q3 2026 - Filings